10.97
2.49%
-0.28
After Hours:
10.97
Pieris Pharmaceuticals Inc stock is currently priced at $10.97, with a 24-hour trading volume of 5,652.
It has seen a -2.49% decreased in the last 24 hours and a +6,883% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $11.20 pivot point. If it approaches the $11.00 support level, significant changes may occur.
Previous Close:
$11.25
Open:
$11.5399
24h Volume:
5,652
Market Cap:
$13.57M
Revenue:
$42.81M
Net Income/Loss:
$-24.54M
P/E Ratio:
-29.65
EPS:
-0.37
Net Cash Flow:
$-53.99M
1W Performance:
-1.61%
1M Performance:
+6,883%
6M Performance:
+4,760%
1Y Performance:
+1,263%
Pieris Pharmaceuticals Inc Stock (PIRS) Company Profile
Name
Pieris Pharmaceuticals Inc
Sector
Industry
Phone
857-246-8998
Address
255 State Street, 9th Floor, Boston, MA
Pieris Pharmaceuticals Inc Stock (PIRS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-13-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
Jul-30-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
May-14-19 | Initiated | Robert W. Baird | Outperform |
Mar-19-18 | Initiated | Evercore ISI | Outperform |
Mar-19-18 | Initiated | Jefferies | Buy |
Jan-16-18 | Reiterated | H.C. Wainwright | Buy |
May-30-17 | Initiated | Rodman & Renshaw | Buy |
Aug-05-16 | Resumed | ROTH Capital | Buy |
Aug-12-15 | Initiated | JMP Securities | Mkt Outperform |
Jul-27-15 | Initiated | Oppenheimer | Outperform |
Jul-22-15 | Initiated | ROTH Capital | Buy |
View All
Pieris Pharmaceuticals Inc Stock (PIRS) Latest News
Pieris Pharmaceuticals (PIRS) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Lifestyle UK
Yahoo Lifestyle UK
PIRS Stock Earnings: Pieris Pharmaceuticals Reported Results for Q1 2024 - MSN
MSN
Pieris Pharmaceuticals (NASDAQ:PIRS) Earns Hold Rating from Analysts at StockNews.com - Defense World
Defense World
Pieris Pharmaceuticals: Q1 Earnings Snapshot - Milford Mirror
Milford Mirror
Pieris Pharmaceuticals (PIRS) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Movies Canada
Yahoo Movies Canada
What You Need To Know About Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Investor Composition - Yahoo Movies UK
Yahoo Movies UK
Pieris Pharmaceuticals Inc Stock (PIRS) Financials Data
Pieris Pharmaceuticals Inc (PIRS) Revenue 2024
PIRS reported a revenue (TTM) of $42.81 million for the quarter ending December 31, 2023, a +65.28% rise year-over-year.
Pieris Pharmaceuticals Inc (PIRS) Net Income 2024
PIRS net income (TTM) was -$24.54 million for the quarter ending December 31, 2023, a +26.25% increase year-over-year.
Pieris Pharmaceuticals Inc (PIRS) Cash Flow 2024
PIRS recorded a free cash flow (TTM) of -$53.99 million for the quarter ending December 31, 2023, a +11.45% increase year-over-year.
Pieris Pharmaceuticals Inc (PIRS) Earnings per Share 2024
PIRS earnings per share (TTM) was -$0.28 for the quarter ending December 31, 2023, a +37.78% growth year-over-year.
About Pieris Pharmaceuticals Inc
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. The company is involved in developing PRS-343, a bispecific protein that is in Phase I clinical trial for oncology diseases; PRS-332, a bispecific anticalin-antibody fusion protein that is in preclinical evaluation stage for oncology diseases; PRS-080 that is in Phase IIa clinical trial to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; and PRS-060, a drug candidate, which is in Phase I clinical trial that binds to the IL- 4Ra receptor for the treatment of asthma and other inflammatory diseases, as well as other drugs. It has strategic partnerships with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seattle Genetics Inc., as well as others; and non-strategic license or option agreements with Aska Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc., Sanofi Group, Allergan Sales, LLC, Allergan, Inc., and Allergan Pharmaceuticals Holdings (Ireland) Unlimited Company, as well as license agreements with TUM, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
Cap:
|
Volume (24h):